Literature DB >> 7659200

Caffeine use: is there a net benefit for mood and psychomotor performance?

P J Rogers1, N J Richardson, C Dernoncourt.   

Abstract

We agree with the conclusions of a recent article in this journal [James, Neuropsychobiology 1994;30:124-125] that studies on the psychoactive effects of caffeine need to take into account the possibility that the results obtained might represent merely the reversal of deleterious effects of caffeine deprivation rather than an actual net benefit due to caffeine use. However, in a review of recent studies we find no unequivocal evidence of impaired psychomotor performance associated with caffeine withdrawal. This is in contrast to a clear deterioration of mood which occurs even after overnight caffeine deprivation. We concluded that current evidence points to true performance-enhancing effects of caffeine, although the extent of these and the conditions under which caffeine is most effective have yet to be fully determined. At the same time, the existence of significant detrimental effects of caffeine deprivation on psychomotor performance has not been ruled out.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7659200     DOI: 10.1159/000119192

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  2 in total

1.  Overnight caffeine abstinence and negative reinforcement of preference for caffeine-containing drinks.

Authors:  P J Rogers; N J Richardson; N A Elliman
Journal:  Psychopharmacology (Berl)       Date:  1995-08       Impact factor: 4.530

2.  Genome-wide association analysis of coffee drinking suggests association with CYP1A1/CYP1A2 and NRCAM.

Authors:  N Amin; E Byrne; J Johnson; G Chenevix-Trench; S Walter; I M Nolte; J M Vink; R Rawal; M Mangino; A Teumer; J C Keers; G Verwoert; S Baumeister; R Biffar; A Petersmann; N Dahmen; A Doering; A Isaacs; L Broer; N R Wray; G W Montgomery; D Levy; B M Psaty; V Gudnason; A Chakravarti; P Sulem; D F Gudbjartsson; L A Kiemeney; U Thorsteinsdottir; K Stefansson; F J A van Rooij; Y S Aulchenko; J J Hottenga; F R Rivadeneira; A Hofman; A G Uitterlinden; C J Hammond; S-Y Shin; A Ikram; J C M Witteman; A C J W Janssens; H Snieder; H Tiemeier; B H R Wolfenbuttel; B A Oostra; A C Heath; E Wichmann; T D Spector; H J Grabe; D I Boomsma; N G Martin; C M van Duijn
Journal:  Mol Psychiatry       Date:  2011-08-30       Impact factor: 15.992

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.